The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
追加情報Flow Cyt: Use 0.25 µg for 106 cells.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
機能Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
関連疾患Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
Antibody deficiency due to defect in CD19, included antibody
B lymphocyte antigen CD19 antibody
B lymphocyte surface antigen B4 antibody
B-lymphocyte antigen CD19 antibody
B-lymphocyte surface antigen B4 antibody
CD19 antigen antibody
CD19 molecule antibody
Cd19 protein antibody
Differentiation antigen CD19 antibody
Leu 12 antibody
T-cell surface antigen Leu-12 antibody
Anti-CD19 antibody [1D3] 画像
Flow Cytometry - CD19 antibody [1D3] (ab86902)
ab86902 and an FITC conjugated anti mouse CD3 antibody, used at a concentration of 0.25 µg/106 cells, staining CD19 in mouse splenocytes by cell surface flow cytometric analysis. An anti rat PE secondary antibody was used.
Anti-CD19 antibody [1D3] (ab86902) 使用論文
has not yet been referenced specifically in any publications.